Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Affymax
With that in mind, let's take a closer look at Affymax's business and see what CAPS investors are saying about the stock right now.
Affymax facts
| Headquarters (founded) | Palo Alto, Calif. (2001) |
| Market Cap | $452.2 million |
| Industry | Biotechnology |
| Trailing-12-Month Revenue | $47.7 million |
| Management |
CEO John Orwin CFO Herbert Cross |
| Cash/Debt | $98.5 million / $0.0 million |
| Competitors |
Amgen Roche Johnson & Johnson |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 24% of the 132 members who have rated Affymax believe the stock will underperform the S&P 500 going forward.
Earlier this week, one of those bears, All-Star TSIF, touched on the stock's seemingly unsustainable valuation:
I suspect the share price and the drug sales of Omontys will be rather ANEMIC in the ... short run.
Overall ... approval of Affymax's injectable drug Omontys, once [monthly] for those with kidney disease, should be lower cost than the monopoly drugs currently on the market.
The rise in share price prior to the announcement pretty much values Affymax [fairly] for now, especially with the split that will go to [Takeda Pharmaceutical]. ... The road to production is generally long and those investing in FDA catalyst drugs are generally not loyal.
If you want to retire rich, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so access it now.
